Skip to main content
. 2020 Jul 28;76(12):1639–1651. doi: 10.1007/s00228-020-02967-0

Table 3.

Major study outcomes

Median OS (months) Median PFS (months) Overall response rate (%)
Trial Statin group Control group HR (95% CI), p value Statin group Control group HR (95% CI), p value Statin Control p value
Alexandre et al. [21] NS NS HR 1.56 (0.14-17.28), p = 0.716 NS NS HR 0.78 (0.11-5.61), p = 0.807 NS NS NS
Jouve et al. [22] 10.7 (7.7–14.3) 10.5 (8.2–12.4) 1.00 (0.79–1.28), p = 0.975 5.0 (3.4–6.0) 4.4 (3.3–5.6) 1.00 (0.80–1.25), p = 0.986 NS NS NS
Lee et al. [23] 10.0 (6.4–13.8) 7.0 (6.1–7.9) 1.03 (0.58–1.80), p = 0.466 1.0 (0.5–1.4) 3.6 (3.0–4.1) 1.38 (0.84–2.29), p = 0.898 5.70% 9.40% 0.43
Seckl et al. [24] 10.7 10.6 1.01 (0.88–1.16), p = 0.90 7.7 7.3 0.98 (0.85–1.13), p = 0.81 69% 69.10% 0.963c
El-Hamamsy et al. [25] 3.4 (0.69–6.01) 3 (2.46–3.54) NS, p = 0.880 1.6 (0.68–2.52) 1.47 (0.91–2.02) NS, p = 0.392 78.6%b 60%b 0.427
Lim et al. [26] 15.3 (12.1–18.5) 19.2 (16.8–21.6) NS, p = 0.826a 5.9 (4.5–7.3) 7 (5.4–8.6) 1.03 (0.77–1.37), p = 0.858 11.90% 11.80% 1
Kim et al. [27] 11.6 (9.2–13.9) 11.5 (9.9–13.1) NS, p = 0.818 5.2 (4.3–6.1) 4.6 (3.5–5.7) 0.93 (0.68–1.26), p = 0.664 27.50% 29.00% 0.936
Hong et al. [28] 6.6 (4.4–8.2) 8.7 (4.8–12.6) NS, p = 0.98 2.4 (0.7–4.1) 3.6 (3.1–4.1) NS, 0.903 6.90% 14.30% 0.23
Han et al. [29] 13.6 (7.1–20.1) 12 (7.8–16.2) 0.88 (0.57–1.35), p = 0.491 3.3 (1.4–5.2) 1.9 (1.0–2.8) 0.891 (0.60–1.32), p = 0.549 38.50% 31.50% 0.666
Konings et al. [30] 8 (3.02–12.98) 6 (4.93–7.08) NS 6 (3.39–8.61) 5 (3.83–6.17) NS 33.30% 46.70% 0.473
Kawata et al. [31] 18 9 0.42 (0.20–0.83), p = 0.006 NS NS NS NS NS NS

NS not stated, OS overall survival, PFS progression-free survival

Figures in parenthesis indicate 95% confidence intervals

ap value calculated using log-rank test

bRadiological response

cp value calculated using chi-squared test

Figures in parenthesis indicate 95% confidence intervals